{"id":"pf-07899895","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"Not studied; Phase 1 terminated before reproductive toxicology assessment","Geriatric use":"Not studied","Paediatric use":"Not studied","Renal impairment":"Not studied","Hepatic impairment":"Not studied"},"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06137729"],"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2020","type":"neutral","milestone":"Phase 1 initiation in healthy volunteers","regulator":"none","description":"A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults initiated by Pfizer (N=37)"},{"date":"2023","type":"negative","milestone":"Phase 1 trial terminated","regulator":"none","description":"Phase 1 study in healthy adults was terminated; program discontinued and not advanced to Phase 2"}],"aiSummary":"PF-07899895 is an experimental small-molecule compound developed by Pfizer that was discontinued during early clinical development. The drug completed only a Phase 1 safety and tolerability study in healthy adults (N=37), which was terminated, indicating the program did not advance to later-stage trials. Without disclosed mechanism of action, molecular target, or indication focus, the compound's therapeutic class and clinical differentiation remain undisclosed. The termination suggests either safety concerns, lack of efficacy signals, or strategic portfolio prioritization by Pfizer. No regulatory approvals were achieved, no commercial revenue was generated, and the program has no ongoing development or market presence. This asset represents a failed early-stage pipeline candidate with no current clinical or commercial significance.","brandName":"PF-07899895","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Not disclosed","novelty":"me-too","modality":"small molecule","drugClass":"Unknown","explanation":"PF-07899895 did not progress beyond Phase 1 clinical evaluation, and Pfizer has not publicly disclosed the molecular target, mechanism of action, or intended therapeutic pathway for this compound. The single Phase 1 trial in healthy volunteers was terminated, preventing the collection of sufficient pharmacokinetic, pharmacodynamic, or safety data needed to characterize how the drug acts in the body. Without completion of Phase 1, the drug's binding mechanism, selectivity profile, and biological activity remain unknown to the public domain.","oneSentence":"Mechanism of action not disclosed; Phase 1 study terminated before pharmacological characterization.","technicalDetail":"No technical pharmacology data available. Phase 1 trial termination (N=37, healthy volunteers) prevented characterization of molecular target, binding kinetics, selectivity, or pharmacokinetic parameters. Mechanism class undisclosed."},"_companyIR":{"irUrl":"https://pfizerinc.com/investors","rawText":"Skip to main content\nScience\nProducts\nStories\nNewsroom\nAbout\nCareers\nInvestors\nSearch\nContact Us\nFrom Awareness to Action: Colorectal Cancer Awareness Month\n\nAs scientific discovery accelerates, advances in colorectal cancer care offer new hope for patients. See how Pfizer is helping reshape what's possible.\n\n \n\nExplore with us\n\n2025 Annual Review: Pfizer’s Bold Moves\n\nSharpening our science from oncology to obesity, we’re striving to expand what’s possible for those who rely on us.\n\nDiscover more\n\nLatest Articles\n\n03.27.2026\n\n|\n\nARTICLE\n\nSpotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection\n\n03.25.2026\n\n|\n\nARTICLE\n\nAs Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever\n\n03.19.2026\n\n|\n\nARTICLE\n\nPfizer Among World’s Most Ethical Companies for 5th Straight Year\n\n03.12.2026\n\n|\n\nARTICLE\n\nCEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review\n\n03.10.2026\n\n|\n","revenueRefs":[],"pipelineRefs":[]},"commercial":{"notes":"Program discontinued; no commercial development or market entry","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"no"},"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pf-07899895","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Undisclosed indication (Phase 1 terminated)","notes":"Single Phase 1 trial in healthy adults (N=37) was terminated; no indication formally disclosed by Pfizer","phase":"Phase 1","status":"completed"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06137729","phase":"PHASE1","title":"A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-11-17","conditions":"Healthy","enrollment":37,"completionDate":"2025-10-24","primaryEndpoint":"AE observed after single or multiple doses"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💊","route":"other","frequency":"Not determined","formulation":"Not disclosed"},"_hyperScrapedAt":"2026-03-27T18:21:23.010484","crossReferences":{"chemblId":"CHEMBL4518706","pubchemSID":"521414948"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[{"notes":"Pfizer developed PF-07899895 as an internal pipeline candidate; program discontinued during Phase 1","period":"2020–2023","companyName":"Pfizer Inc.","relationship":"Originator"}],"therapeuticAreas":["Other"],"trialPhaseCounts":{"PHASE1":1},"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"small molecule","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}